Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Uterine Fibroid Treatment Device Market Size & Share 2026-2035
Report ID: GMI14194
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Uterine Fibroid Treatment Device Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Uterine Fibroid Treatment Device Market Size
The uterine fibroid treatment device market was valued at USD 7.40 billion in 2025 and is projected to reach USD 7.94 billion in 2026, advancing at a 7.8% CAGR from 2026 to 2035 to arrive at USD 15.73 billion by 2035.
Uterine Fibroid Treatment Device Market Key Takeaways
Market Leader: Hologic led with over 7.4% market share in 2025.
Leading Players: Top 5 players in this market include Hologic, Medtronic, J&J/Ethicon, Olympus, Karl Storz, which collectively held a market share of 29% in 2025.
The Uterine Fibroid Treatment Device Market encompasses the devices, instruments, systems, consumables, and accessories used in surgical, laparoscopic, ablation, embolization, and image-guided fibroid procedures. Market expansion reflects a shift toward uterus-preserving care, outpatient procedural models, and technologies that can reduce tissue disruption while improving physician control and patient recovery pathways.
GMI Analyst View
Based on our demand-side assessment of manufacturer commercial disclosures and healthcare facility procurement data, the global uterine fibroid treatment device market generated revenue of USD 6.01 billion in 2022. This figure confirms that the market entered the current period of commercial expansion with an established procedural base shaped by investments in minimally invasive GYN platforms, broader treatment awareness, and increasing availability of specialized care beyond academic medical centers.
Uterine Fibroid Treatment Device Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is being reshaped by a larger diagnosed patient pool and by clinical preference for treatments that preserve the uterus and support shorter recovery. Commercial adoption, however, remains uneven because reimbursement, capital budgets, specialist availability, and procedural economics differ materially among care settings and geographies.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Fibroid disease burden provides the underlying utilization base for the category, but the commercial effect depends on diagnostic access, referral pathways, and the ability of providers to offer an alternative to definitive surgery. As more patients enter treatment pathways earlier, manufacturers can address demand across both established surgical settings and newer energy-based, catheter-based, and image-guided procedural environments. The opportunity is especially consequential where expanding imaging access is bringing previously untreated symptomatic patients into formal gynecological care.
Strategic portfolio investment can change category adoption more materially than a single product launch. When a transcervical ablation platform enters the commercial infrastructure of an established women's health supplier, the resulting sales-force coverage, physician education capacity, and market-access resources can improve institutional familiarity with the procedure. This can shorten the transition from clinical interest to formulary review and routine case scheduling.[3]Seiffert D., MedTech Dive. “Hologic to buy Gynesonics for $350M to acquire fibroid system.” medtechdive.com
Regulatory pathways also influence the cadence of product refinement. FDA clearance of iterative modifications to established systems gives manufacturers a clearer route to incorporate clinical feedback, improve usability, and maintain product roadmaps without resetting the development process. That continuity supports investment in physician training and allows hospitals to evaluate technology families rather than isolated product generations.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Procedural economics create a layered access barrier because they affect payer authorization, hospital capital allocation, and patient affordability at the same time. A modality may offer a clinically attractive uterus-preserving option yet remain difficult to scale when its episode-of-care cost is not aligned with prevailing reimbursement or facility utilization priorities. Community providers are particularly likely to defer investment when advanced technology requires dedicated infrastructure or specialist support.
The gap between diagnosed disease and minimally invasive utilization is also a training and workflow issue. Physicians require procedural confidence and referral relationships, while patients must receive timely information about options beyond hysterectomy or conventional myomectomy. These frictions can sustain demand for established instruments even where less invasive approaches have compelling clinical rationale, slowing the commercial conversion of the eligible population. [5]Huynh M et al. “Temporal analysis of uterine fibroid treatment modalities: a large healthcare claims-based retrospective study from 2009-2022.” oatext.com
Reimbursement uncertainty is most consequential for premium platforms whose purchase justification depends on predictable procedure volume. Inconsistent coverage can delay hospital procurement decisions, complicate patient counseling, and constrain the formation of repeatable referral pathways. Manufacturers therefore need to pair product innovation with market-access engagement, provider education, and evidence generation that addresses payer concerns.
GMI Analyst View
We view the market as being in a managed transition rather than a wholesale replacement cycle. Conventional surgery will remain commercially important because it is embedded in established care pathways, while laparoscopic and ablation platforms gain ground where hospitals can align training, scheduling, and reimbursement. The principal sensitivity is not clinical interest, but the speed at which providers can operationalize newer modalities.
Uterine Fibroid Treatment Device Market Segment Analysis
By Technology Type
The Uterine Fibroid Treatment Device Market is segmented by technology type across surgical, laparoscopic, ablation, and embolization techniques. Each technology addresses a different combination of fibroid anatomy, physician capability, procedural setting, recovery expectations, and reimbursement conditions.
The Surgical segment generated USD 2.96 billion in 2025 and is projected to account for 32.0% of market revenue in 2035.
Surgical instruments retain a foundational role in fibroid care because open and hysteroscopic procedures remain accessible across a broad range of hospital settings. Their relative position is being pressured by alternatives that support shorter stays and uterus preservation, although established clinical familiarity and wide availability continue to anchor demand.
The Laparoscopic segment is projected to reach USD 5.50 billion by 2035 and is expected to advance at a 9.5% CAGR from 2026 to 2035.
Laparoscopic systems benefit from their fit with ambulatory surgery workflows and from the ability to combine visualization, access, dissection, and energy tools within established GYN practice. Growth is reinforced where surgeons can extend existing laparoscopic skills into fibroid-specific procedures without requiring the infrastructure intensity associated with fully non-invasive platforms.
The Ablation segment accounted for an 18.0% market share in 2025 and is forecast to grow at a 10.0% CAGR from 2026 to 2035.
Ablation is gaining strategic importance because it serves patients seeking symptom relief with lower tissue disruption and, in certain settings, without a major incision. The category includes distinct technology pathways with different adoption barriers, allowing manufacturers to address outpatient, hospital, and specialized imaging-centered environments through differentiated platforms.
The Embolization Techniques segment is projected to represent 11.0% of market revenue in 2035 and generated USD 888 million in 2025.
Embolization remains clinically relevant for uterus-preserving treatment, particularly where interventional radiology services are available and referral networks are well established. Its expansion is moderated by procedural cost scrutiny, the need for specialized vascular expertise, and competition from energy-based solutions that may be easier for gynecology-led care pathways to adopt.
By Treatment Type
The Uterine Fibroid Treatment Device Market is also defined by treatment type, reflecting the broader shift from open intervention toward procedures that reduce recovery time and preserve treatment choice for patients.
The Invasive segment generated USD 2.22 billion in 2025 and is projected to account for 22.0% of market revenue in 2035.
Invasive procedures remain necessary for complex clinical presentations and continue to support demand for conventional surgical instruments. Nevertheless, their relative role is declining as hospitals seek to reduce inpatient burden and as patients increasingly evaluate treatment options through the lens of recovery, fertility considerations, and procedural invasiveness.
The Minimally Invasive segment is projected to reach USD 9.75 billion by 2035 and held a 58.0% market share in 2025.
Minimally invasive treatment is the market's central commercial engine because it encompasses multiple established and emerging pathways, including laparoscopic surgery, hysteroscopic intervention, embolization, and radiofrequency ablation. Portfolio breadth is a competitive advantage in this segment, as providers often require different solutions for different fibroid locations, patient preferences, and care settings.
The Non-Invasive segment is expected to expand at an 11.0% CAGR from 2026 to 2035 and is projected to represent 16.0% of market revenue in 2035.
Non-invasive platforms are differentiated by their potential to avoid surgical or catheter access, but their penetration depends heavily on imaging capacity, specialist coordination, and payer acceptance. The segment is likely to develop most effectively in centers that can establish reliable patient throughput and integrate treatment selection into a broader fibroid care pathway.
GMI Analyst View
We believe technology adoption will favor solutions that reduce procedural friction as well as clinical invasiveness. Laparoscopic platforms are well positioned because they align with existing surgical capability and outpatient economics, while non-invasive systems face a longer institutionalization cycle. Their future commercial impact will depend on whether hospitals can convert patient interest into repeatable, reimbursed service lines.
Uterine Fibroid Treatment Device Market Regional Analysis
North America Uterine Fibroid Treatment Device Market Analysis
The North America Uterine Fibroid Treatment Device Market accounted for 40.0% of global revenue in 2025 and is projected to generate USD 6.00 billion by 2035.
North America remains the leading regional market because it combines high procedural sophistication with mature reimbursement and a dense base of ambulatory, hospital, and specialist care providers. The region offers manufacturers a comparatively developed environment for product launches, training initiatives, and adoption of premium procedural technologies.
United States
The U.S. market generated USD 2.59 billion in 2025 and is projected to reach USD 5.25 billion by 2035.
The U.S. is the most consequential national market for platform commercialization because regulatory clarity, subspecialty depth, and diverse care-site infrastructure support adoption across technology categories. Manufacturers can use the market to build procedural evidence, develop physician champions, and establish reimbursement narratives that influence broader international adoption.
Canada
Canada held a 5.0% global market share in 2025 and is projected to grow at a 7.3% CAGR from 2026 to 2035.
Canadian adoption is supported by broad access to established gynecological care, although premium-platform uptake can move more gradually through provincial assessment and procurement processes. The market rewards technologies that demonstrate a clear clinical and operational fit within publicly funded care systems.
Europe Uterine Fibroid Treatment Device Market Analysis
The Europe Uterine Fibroid Treatment Device Market generated USD 2.07 billion in 2025 and is projected to account for 26.1% of global revenue in 2035.
Europe combines mature gynecological surgery infrastructure with heterogeneous reimbursement, coding, and procurement systems. The regional opportunity is therefore less about uniform adoption and more about country-specific execution, particularly for manufacturers seeking to broaden use of ablation and advanced minimally invasive platforms.
Germany
Germany generated USD 414 million in 2025 and is projected to reach USD 779 million by 2035.
Germany's hospital infrastructure and established surgical specialization support demand for laparoscopic, hysteroscopic, and energy-based platforms. Its importance lies in the ability of providers to incorporate advanced procedures into organized hospital service lines while maintaining access to a large insured patient base.
United Kingdom
The UK is projected to account for 4.4% of global market revenue in 2035 and held a 5.0% share in 2025.
The UK market is shaped by centralized evaluation, public procurement, and the pace at which clinical guidance translates into local service delivery. Demand for advanced devices is likely to favor solutions that can demonstrate both procedural value and compatibility with resource-constrained hospital workflows.
France
France generated USD 331 million in 2025 and is projected to account for 4.0% of global market revenue in 2035.
France offers a strong setting for fibroid technologies that can be integrated across gynecology and interventional radiology. Its clinical base supports uterus-preserving treatment, while the pace of adoption remains tied to reimbursement alignment and the capacity of public hospitals to standardize newer pathways.
Italy
Italy is projected to generate USD 554 million by 2035 and held a 3.9% global market share in 2025.
Italian demand is supported by established hysteroscopic expertise and growing interest in treatments that preserve the uterus. Adoption patterns vary between public and private settings, creating opportunities for suppliers that can support both institutional procurement and physician-led technology diffusion.
Spain
Spain held a 3.4% global market share in 2025 and is projected to generate USD 492 million by 2035.
Spain's mixed healthcare environment supports uneven but meaningful expansion of minimally invasive gynecological procedures. Private hospital networks are an important channel for advanced platforms, while broader penetration depends on training availability and the economics of introducing new modalities into public care settings.
Netherlands
The Netherlands is projected to account for 1.8% of global market revenue in 2035 and is expected to advance at a 7.1% CAGR from 2026 to 2035.
The Dutch market is characterized by a centralized, evidence-oriented healthcare system that can support efficient uptake once clinical value is established. Suppliers with clear procedural evidence and implementation support are positioned to benefit as hospitals expand access to minimally invasive care.
Asia Pacific Uterine Fibroid Treatment Device Market Analysis
The Asia Pacific Uterine Fibroid Treatment Device Market accounted for 22.0% of global revenue in 2025 and is forecast to grow at a 9.7% CAGR from 2026 to 2035.
Asia Pacific is the fastest-growing regional opportunity, supported by rising diagnostic access, expanding hospital capacity, and greater willingness among patients to pursue uterus-preserving care. The region's scale makes localized commercial infrastructure, clinical education, and channel strategy essential to converting demand into device utilization. South Asia also carries the highest absolute fibroid burden among GBD regions, reinforcing the long-term importance of the region for treatment access and procedural capacity.
China
China held a 7.7% global market share in 2025 and is projected to generate USD 1.51 billion by 2035.
China's market is supported by continued tertiary-hospital development, increasing minimally invasive surgical capacity, and a growing mix of domestic and multinational device offerings. The country's established experience with focused-ultrasound treatment creates a relevant foundation for broader adoption of advanced fibroid care technologies.
Japan
Japan is projected to account for 4.4% of global market revenue in 2035 and generated USD 358 million in 2025.
Japan's highly developed clinical infrastructure supports sophisticated gynecological care, but adoption generally follows a deliberate evidence-based path. Suppliers must demonstrate incremental value within a system where demographic changes and cautious technology evaluation shape the pace of procedural expansion.
India
India is expected to advance at a 12.4% CAGR from 2026 to 2035 and is projected to account for 4.7% of global market revenue in 2035.
India represents a high-priority development market because its disease burden, private-hospital investment, and expanding healthcare access can support substantial growth in treatment capacity. Commercial success will depend on technologies that can be supported through physician education, cost-sensitive procurement, and increasingly diversified care delivery models.
Australia
Australia held a 2.2% global market share in 2025 and is projected to generate USD 327 million by 2035.
Australia's well-resourced public-private system supports adoption of advanced gynecological technologies and makes the country an influential early-adoption market within Asia Pacific. Its providers can serve as reference sites for newer approaches that require disciplined clinical implementation and patient-selection protocols.
South Korea
South Korea generated USD 195 million in 2025 and is forecast to grow at a 9.7% CAGR from 2026 to 2035.
South Korea benefits from technologically sophisticated hospitals and broad physician familiarity with minimally invasive care. The market is positioned to adopt a diverse set of laparoscopic, ablation, and imaging-linked solutions where they can be incorporated into high-throughput tertiary-care environments.
Latin America
The Latin America Uterine Fibroid Treatment Device Market held a 6.0% global market share in 2025 and is projected to generate USD 1.01 billion by 2035.
Latin America presents an expanding but uneven opportunity, with advanced adoption concentrated in major urban centers and private hospital networks. Demand growth will depend on improved diagnostic pathways, training capacity, and financing structures that make minimally invasive procedures available beyond affluent metropolitan populations. Regional disease-burden trends support the long-term clinical need for broader treatment access.
Brazil
Brazil generated USD 200 million in 2025 and is projected to reach USD 444 million by 2035.
Brazil is Latin America's largest country market, supported by a substantial private hospital sector and developing uptake of laparoscopic and ablation technologies. Its mixed payer environment favors suppliers that can address premium private demand while building pathways for wider adoption across the health system.
Mexico
Mexico is projected to generate USD 303 million by 2035 and held a 1.8% global market share in 2025.
Mexico's market development is centered on metropolitan private providers, where minimally invasive capability is expanding. Broader growth depends on overcoming equipment cost and training barriers in public-sector settings, where established surgical techniques remain more accessible.
Argentina
Argentina held a 0.7% global market share in 2025 and is projected to grow at an 8.6% CAGR from 2026 to 2035.
Argentina's clinical base can support growth in laparoscopic and hysteroscopic procedures, but commercial execution is influenced by procurement volatility and import logistics. Manufacturers with flexible distribution and service models are better positioned to maintain continuity in this environment.
Middle East & Africa Uterine Fibroid Treatment Device Market Analysis
The Middle East & Africa Uterine Fibroid Treatment Device Market generated USD 296 million in 2025 and is projected to reach USD 535 million by 2035.
Middle East & Africa encompasses sharply different market conditions, ranging from premium Gulf healthcare systems to markets constrained by limited specialist access, financing, and procedural infrastructure. The region's opportunity is therefore selective, with demand strongest where hospital investment is paired with the capacity to train and retain specialized clinical teams.
South Africa
South Africa held a 0.9% global market share in 2025 and is expected to grow at a 5.1% CAGR from 2026 to 2035.
South Africa has comparatively advanced private-sector clinical infrastructure, but access remains uneven across the wider healthcare system. Advanced-device adoption is consequently concentrated in urban providers that can support specialist care and absorb the financial requirements of newer procedural platforms.
Saudi Arabia
Saudi Arabia is projected to generate USD 177 million by 2035 and generated USD 95 million in 2025.
Saudi Arabia's hospital investment agenda is strengthening the foundation for minimally invasive gynecological care. Demand will be supported by expanding service capacity, recruitment of specialized clinicians, and the development of higher-acuity treatment offerings within large hospital networks.
United Arab Emirates
The UAE held a 1.0% global market share in 2025 and is projected to generate USD 150 million by 2035.
The UAE functions as a premium regional center for advanced gynecological services and medical tourism. Its providers are well placed to adopt robotic, energy-based, and image-guided solutions, although the market remains dependent on concentrated flagship-hospital demand rather than broad-based regional access.
GMI Analyst View
We see regional divergence as a structural feature of this market. North America will remain commercially influential because of its mature reimbursement and provider ecosystem, while Asia Pacific offers the strongest incremental growth potential as treatment capacity broadens. In Latin America and Middle East & Africa, sustained progress will depend less on product availability than on financing, specialist training, and care-site readiness.
Uterine Fibroid Treatment Device Market Share & Competitive Landscape
The Uterine Fibroid Treatment Device Market share landscape is moderately concentrated among major diversified suppliers while remaining fragmented across procedural niches and regional channels. The top five companies Hologic, Medtronic,Johnson & Johnson (Ethicon),Olympus,Karl Storz collectively accounted for approximately 29.0% of global market revenue in 2025, reflecting the breadth of technologies required across hysteroscopic, laparoscopic, ablation, embolization, and image-guided treatment pathways.
Market competition in the uterine fibroid treatment device market is driven by technological innovation, clinical efficacy, procedural safety, physician expertise, and the ability to offer a broad range of treatment solutions across surgical, laparoscopic, ablation, and embolization techniques. Manufacturers compete based on treatment precision, minimally invasive capabilities, preservation of uterine function, reduced recovery times, and long-term patient outcomes. Established players benefit from strong relationships with gynecologists, interventional radiologists, and hospitals, alongside regulatory approvals, clinical evidence, physician training programs, and established distribution networks, creating significant barriers to entry for smaller competitors.
Boston Scientific and Merit Medical Systems are relevant competitors in embolization through vascular access, catheter, and embolic product portfolios. Insightec is a specialized competitor in MRI-guided focused ultrasound, while Minerva Surgical, Terumo Corporation, Conmed, CooperSurgical, Canyon Medical, Nesa Medtech, and Shenzhen Mindray Bio-Medical Electronics participate through complementary gynecological, endoscopic, imaging, energy-based, or procedural-access product lines. Competition is therefore defined not only by share, but by the ability to secure physician preference, maintain service support, navigate reimbursement, and build coherent treatment portfolios.
Recent Industry Developments
KPJ Healthcare's Damansara Specialist Hospital 2 launched a Supine High-Intensity Focused Ultrasound program for non-invasive uterine fibroid treatment through a collaboration with Delta Medisains. The initiative signals growing institutional interest in HIFU-based care in Southeast Asia and supports the development of technical expertise and clinical support for non-invasive fibroid treatment pathways. [6]Free Malaysia Today. “KPJ's DSH2 launches region's first Supine HIFU fibroid treatment programme.” freemalaysiatoday.com
Virtual Incision Corporation received FDA 510(k) clearance for its MIRA Surgical System for benign hysterectomy procedures. The system's compact robotic-assisted design may broaden access to minimally invasive gynecological surgery among hospitals and ambulatory care sites that lack the space or capital profile associated with conventional robotic platforms. [7]Virtual Incision Corporation. “Virtual Incision Receives FDA 510(k) Clearance for the MIRA™ Surgical System in Benign Hysterectomy Procedures.” virtualincision.com
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →